NYSEAMERICAN:AMPE

Ampio Pharmaceuticals - AMPE Stock Forecast, Price & News

$0.10

0.00 (0.00%)

(As of 08/12/2022 12:00 AM ET)

Add

Compare

Today's Range: $0.10
▼
$0.11
50-Day Range: N/A
52-Week Range: $0.09
▼
$1.83

Volume: 6.37 million shs
Average Volume: 3.46 million shs
Market Capitalization: $23.47 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Ampio Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 2,793.0% Upside
$3.00 Price Target
Short Interest: Healthy
5.64% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.67 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Ampio Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.00, Ampio Pharmaceuticals has a forecasted upside of 2,793.0% from its current price of $0.10.
Amount of Analyst Coverage
Ampio Pharmaceuticals has received no research coverage in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
5.64% of the outstanding shares of Ampio Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Ampio Pharmaceuticals has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Ampio Pharmaceuticals has recently decreased by 2.30%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Ampio Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Ampio Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for AMPE.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Ampio Pharmaceuticals this week, compared to 0 articles on an average week.
Search Interest
9 people have searched for AMPE on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Ampio Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Ampio Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.59% of the stock of Ampio Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 21.88% of the stock of Ampio Pharmaceuticals is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Ampio Pharmaceuticals are expected to remain at ($0.07) per share in the coming year.
Price to Earnings Ratio vs. the Market
The P/E ratio of Ampio Pharmaceuticals is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Ampio Pharmaceuticals is -1.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Ampio Pharmaceuticals has a P/B Ratio of 1.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Stock

Ampio Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of immunomodulatory therapies for the treatment of pain from osteoarthritis in the United States. Its product pipeline includes AP-013, an intra-articular injection, which is in phase III clinical trial for the treatment of osteoarthritis of the knee; AP-017, an intravenous ampion treatment that is in Phase II clinical trial to treat adult COVID-19 patients requiring oxygen supplementation; AP-019, an Inhaled Ampion treatment, which is in Phase II clinical trial for the treatment of Adults with Respiratory Distress Due to COVID-19; and AP-018 that is in Phase I clinical trial to treat patients with prolonged respiratory symptoms due to COVID-19. The company is headquartered in Englewood, Colorado.

Receive AMPE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ampio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMPE Stock News Headlines

August 3, 2022 | seekingalpha.com

Ampio announces 55% reduction of staff as key development program ends

August 3, 2022 | marketwatch.com

Ampio Pharmaceuticals Fires Two Executives After Investigation

August 3, 2022 | finance.yahoo.com

Ampio Pharmaceuticals Issues Letter to Stockholders

August 1, 2022 | finance.yahoo.com

6 Penny Stocks With 1,000% Upside Potential

May 17, 2022 | finance.yahoo.com

Ampio's Independent Committee Launches Investigation Related To AP-013 Trial

May 16, 2022 | finance.yahoo.com

Ampio Independent Committee to Conduct Investigation

May 16, 2022 | finance.yahoo.com

Ampio Pharmaceuticals Reports First-Quarter Financial Results

April 27, 2022 | finance.yahoo.com

Ampio Pharmaceuticals, Inc. to Hold Conference Call

April 20, 2022 | finance.yahoo.com

AMPIO PROVIDES REGULATORY UPDATE

March 31, 2022 | seekingalpha.com

Ampio Pharmaceuticals GAAP EPS of -$0.10

March 29, 2022 | finance.yahoo.com

Ampio Pharmaceuticals Reports Fourth-Quarter and Full-Year 2021 Financial Results and Operational Highlights

March 24, 2022 | msn.com

Why Ampio Pharmaceuticals Stock Is Rising Today

March 23, 2022 | finance.yahoo.com

Ampio Pharmaceuticals, Inc. to Hold Fourth Quarter 2021 Earnings and Business Update Call

March 9, 2022 | finance.yahoo.com

Ampio Pharmaceuticals to Participate at the 34th Annual Roth Conference

March 3, 2022 | benzinga.com

Ampio Highlights Promising Ampion Data In Knee Osteoarthritis

March 2, 2022 | finance.yahoo.com

Ampio Pharmaceuticals, Inc. Releases Positive Phase 3 Data Analysis for Ampion™ Targeting Severe Osteoarthritis of the Knee (OAK)

March 2, 2022 | finance.yahoo.com

Ampio Pharmaceuticals, Inc. to Host a Conference Call and Webinar

February 10, 2022 | finance.yahoo.com

Ampio Expands Board of Directors with Addition of Elizabeth Varki Jobes

January 6, 2022 | finance.yahoo.com

Ampio Pharmaceuticals Presents Corporate Overview at H.C. Wainwright Bioconnect Conference

December 16, 2021 | finance.yahoo.com

Ampio Pharmaceuticals' CEO Mike Martino Issues Letter to Stockholders

December 14, 2021 | msn.com

Ampio (AMPE) Upgraded to Buy: Here's What You Should Know

December 13, 2021 | benzinga.com

Ampio Pharma Prices 25M Share, 15M Shares Via Warrants At Combined Price $0.90/Unit

December 13, 2021 | finance.yahoo.com

AMPIO PHARMACEUTICALS ANNOUNCES PRICING OF $22.5 MILLION REGISTERED DIRECT OFFERING

November 29, 2021 | finance.yahoo.com

Ampio Pharmaceuticals to Host Business Update Call with Chairman and CEO Mike Martino on Wednesday, Dec. 1

November 23, 2021 | finance.yahoo.com

Ampio Pharmaceuticals Announces Shareholder / Business Update Call with its CEO & Chairman, Michael Martino

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive AMPE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ampio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AMPE Company Calendar

Last Earnings: 5/16/2022
Today: 8/12/2022
Next Earnings (Estimated): 11/08/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSEAMERICAN
Industry: Pharmaceutical preparations
Sub-Industry: Pharmaceuticals
Sector: Medical
Current Symbol: NYSEAMERICAN:AMPE
Previous Symbol: NYSE:AMPE
CUSIP: 03209T10
CIK: 1411906
Web: ampiopharma.com
Phone: (720) 437-6500
Fax: 720-437-6501
Employees: 20
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.00
High Stock Price Forecast: $3.00
Low Stock Price Forecast: $3.00
Forecasted Upside/Downside: +2,793.0%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.08)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-15,890,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -86.02%
Return on Assets: -65.97%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.95
Quick Ratio: 7.95

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.09 per share
Price / Book: 1.15

Miscellaneous

Outstanding Shares: 226,287,000
Free Float: 194,874,000
Market Cap: $23.47 million
Optionable: Optionable
Beta: 1.51

Key Executives

Mr. Michael A. Martino (Age 65)
CEO & Director
Comp: $585.71k
Dr. David Bar-Or M.D. (Age 73)
Founder & Chairman of Scientific Advisory Board
Comp: $38.5k
Mr. Daniel G. Stokely CPA (Age 58)
CPA, CFO, Corp. Sec. & Treasurer
Comp: $301.36k
Dr. Howard Levy M.B.B.Ch. (Age 68)
M.M.M., Ph.D., Chief Medical Officer
Lane Hapke
VP of Manufacturing Operations
April Ramirez
Clinical Trial Mang.
Laura Goldberg
VP of Quality and Regulatory Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

AMPE Stock - Frequently Asked Questions

Should I buy or sell Ampio Pharmaceuticals stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Ampio Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AMPE shares.
View AMPE analyst ratings or view top-rated stocks.
What is Ampio Pharmaceuticals' stock price forecast for 2022?: 1 Wall Street analysts have issued 12 month price targets for Ampio Pharmaceuticals' shares. Their AMPE share price forecasts range from $3.00 to $3.00. On average, they expect the company's stock price to reach $3.00 in the next year. This suggests a possible upside of 2,867.4% from the stock's current price.
View analysts price targets for AMPE or view top-rated stocks among Wall Street analysts.
Are investors shorting Ampio Pharmaceuticals?: Ampio Pharmaceuticals saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 13,080,000 shares, a decline of 35.0% from the June 15th total of 20,130,000 shares. Based on an average daily volume of 4,510,000 shares, the short-interest ratio is presently 2.9 days. Currently, 15.1% of the shares of the stock are short sold.
View Ampio Pharmaceuticals' Short Interest.
When is Ampio Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our AMPE earnings forecast.
How were Ampio Pharmaceuticals' earnings last quarter?: Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE) issued its earnings results on Monday, May, 16th. The specialty pharmaceutical company reported ($0.03) EPS for the quarter, missing the consensus estimate of ($0.02) by $0.01.

What other stocks do shareholders of Ampio Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Ampio Pharmaceuticals investors own include Trevena (TRVN), Matinas BioPharma (MTNB), Sorrento Therapeutics (SRNE), Bionano Genomics (BNGO), Rigel Pharmaceuticals (RIGL), Cogent Biosciences (UMRX), ADMA Biologics (ADMA), Great Panther Mining (GPL), Zosano Pharma (ZSAN) and Miragen Therapeutics (MGEN).
What is Ampio Pharmaceuticals' stock symbol?: Ampio Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "AMPE."
Who are Ampio Pharmaceuticals' major shareholders?: Ampio Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Courier Capital LLC (0.24%), Capital Wealth Alliance LLC (0.03%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Dan Stokely, Holli Cherevka and Philip H Coelho.
View institutional ownership trends.
How do I buy shares of Ampio Pharmaceuticals?: Shares of AMPE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Ampio Pharmaceuticals' stock price today?: One share of AMPE stock can currently be purchased for approximately $0.10.
How much money does Ampio Pharmaceuticals make?: Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) has a market capitalization of $22.88 million. The specialty pharmaceutical company earns $-15,890,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis.
How can I contact Ampio Pharmaceuticals?: Ampio Pharmaceuticals' mailing address is 373 Inverness Pkwy Ste 200, ENGLEWOOD, CO 80112-5898, United States. The official website for the company is ampiopharma.com. The specialty pharmaceutical company can be reached via phone at (720) 437-6500 or via fax at 720-437-6501.

This page (NYSEAMERICAN:AMPE) was last updated on 8/13/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Ampio Pharmaceuticals - AMPE Stock Forecast, Price & News

Ampio Pharmaceuticals MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Ampio Pharmaceuticals (NYSEAMERICAN:AMPE) Stock

AMPE Stock News Headlines

AMPE Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

AMPE Stock - Frequently Asked Questions

Should I buy or sell Ampio Pharmaceuticals stock right now?

What is Ampio Pharmaceuticals' stock price forecast for 2022?

Are investors shorting Ampio Pharmaceuticals?

When is Ampio Pharmaceuticals' next earnings date?

How were Ampio Pharmaceuticals' earnings last quarter?

What other stocks do shareholders of Ampio Pharmaceuticals own?

What is Ampio Pharmaceuticals' stock symbol?

Who are Ampio Pharmaceuticals' major shareholders?

How do I buy shares of Ampio Pharmaceuticals?

What is Ampio Pharmaceuticals' stock price today?

How much money does Ampio Pharmaceuticals make?

How can I contact Ampio Pharmaceuticals?

MarketBeat Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources

Overall MarketRank^™